Status:
COMPLETED
A Trial of Strontium +/- Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer
Lead Sponsor:
Alberta Health services
Collaborating Sponsors:
The Prostate Cancer Research Foundation of Canada
Amersham Health
Conditions:
Hormone Refractory Prostate Cancer
Bone Metastases
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostat...
Detailed Description
This study is designed to determine whether the combination of low dose cisplatin and strontium-89 shows clinical promise for the symptomatic treatment of bone metastases in hormone refractory prostat...
Eligibility Criteria
Inclusion
- adenocarcinoma of the prostate
- life expectancy \> 3 months,
- symptomatic from bone metastases
- radiologic evidence of metastatic bone disease
- stable level of pain control
- \>18 years
- ability to complete assessments
- prior treatment (chemo) \> 4 weeks previous
- discontinued anti-androgens for \> 4 weeks
Exclusion
- prior strontium therapy
- previous hemibody RT within 6 weeks
- previous cytotoxic chemotherapy within 4 weeks
- use of bisphosphonate medications within 4 weeks
- change in steroid dose within 4 weeks
- active uncontrolled infection
- impending or present spinal cord compression
- significant neurological disorder
- impending pathological fracture
- severe urinary incontinence
Key Trial Info
Start Date :
August 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT00156884
Start Date
August 1 2003
End Date
May 1 2008
Last Update
January 19 2012
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
2
BC Cancer Agency
Vancouver, British Columbia, Canada